Enhanced CTLA4 peptide delivery via PLGA nanoparticles for solid tumor treatment

Overview

This innovative solution involves a PLGA nanoparticle-based system designed to deliver AI-engineered CTLA4 blockade peptides directly to solid tumors. By targeting the tumor microenvironment (TME) using Cilengitide, an integrin αvβ3/αvβ5-binding ligand, this approach aims to alleviate immunosuppression and enhance T-cell infiltration and activation. The use of smaller, AI-designed peptides offers improved tumor penetration compared to traditional antibody-based therapies, potentially reducing systemic autoimmune effects and enhancing treatment efficacy against diverse tumor subclones.

Technical specifications

• AI-designed CTLA4 peptides: Utilizes AI/ML methods like superhelical matching to design peptides with high specificity for CTLA4.
• PLGA nanoparticles: Synthesize nanoparticles that encapsulate CTLA4 peptides, enhancing their delivery and stability.
• Cilengitide targeting: Conjugates to nanoparticle surfaces to target integrins in the TME, promoting selective accumulation.
• In vitro and in vivo validation: Includes testing of uptake, peptide release, and T-cell activation in cancer cell lines and murine tumor models. Measures tumor growth, T-cell infiltration, and cytokine levels for efficacy assessment.

Technology readiness level

This technology is at TRL 2, indicating it is in the early stages of development. Initial in vitro and in vivo validations are planned to further assess its therapeutic potential.